Click Chemistry in Chemical Biology and Drug Development

Displaying 1 - 5 of 5CSV
Amengual, J. E., Shyr, Y., Durecki, D., Beumer, J. H., Mansukhani, M. M., Williams, M., Kelleher, N., Cherng, H., Pro, B., Schwartz, G. K., LoRusso, P., & Piekarz, R. (2023). ETCTN P10500: PHASE 1/EXPANSION STUDY OF TAZEMETOSTAT PLUS BELINOSTAT FOR THE TREATMENT OF RELAPSED OR REFRACTORY LYMPHOMA. Hematological Oncology, 41(S2), 833–834. Portico. https://doi.org/10.1002/hon.3166_ot14
Publication Date
DeAngelo, D. J., Pullarkat, V. A., Piris-Villaespesa, M., George, T. I., Patel, J. L., Ustun, C., Bose, P., Heaney, M. L., Sachs, J., Sun, L., Pilla, A., Exter, B., Jolin, H. A., & Tashi, T. (2022). Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM). Blood, 140(Supplement 1), 1512–1513. https://doi.org/10.1182/blood-2022-156311
Publication Date

DeAngelo, D. J., Pullarkat, V., Piris-Villaespesa, M., George, T. I., Patel, J. L., Ustun, C., Bose, P., Heaney, M. L., Pilla, A., Massaro, M., Exter, B., Jolin, H. A., Mikhak, Z., & Tashi, T. (2022). P1049: A Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent Kit D816V Inhibitor, in Adults With Advanced Systemic Mastocytosis (Apex): Methods, Baseline Data, and Early Insights. HemaSphere, 6, 939–940. https://doi.org/10.1097/01.hs9.0000847064.38588.9b

Publication Date